Plasma anti-DLAT autoantibody as a novel diagnostic biomarker in breast cancer

Key Points

• Anti-DLAT autoantibodies show promise as novel biomarkers for breast cancer diagnoses.
• The analysis indicates significant differences in autoantibody levels between cancer and healthy groups.
• Assessment of plasma samples indicates the potential for anti-DLAT to enhance diagnostic accuracy.
• Detection of anti-DLAT autoantibodies may improve breast cancer screening strategies, suggesting further validation is needed.